Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver-Reference-Cited by-同舟云学术

Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver

Published:2021-02-26 Issue:9 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Kim M.¹^ORCID,Jeong M.¹^ORCID,Hur S.²,Cho Y.²,Park J.³^ORCID,Jung H.¹,Seo Y.¹,Woo H. A.¹,Nam K. T.²^ORCID,Lee K.¹⁴^ORCID,Lee H.¹^ORCID

Affiliation:

1. College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, South Korea.

2. Severance Biomedical Science Institute, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, South Korea.

3. Fluorescence Core Imaging Center, Ewha Womans University, Seoul 120-750, South Korea.

4. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, South Korea.

Abstract

Engineered ionizable lipid nanoparticles (LNPs) were developed for the LSEC-specific delivery of RNA therapeutics.

Funder

Solvay Pharmaceuticals

National Research Foundation of Korea

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference45 articles.

1. Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy

2. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis

3. Systemic delivery of factor IX messenger RNA for protein replacement therapy

4. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins

5. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the design and delivery of RNA vaccines for infectious diseases;Advanced Drug Delivery Reviews;2024-10

2. Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis;Journal of Controlled Release;2024-10

3. Current landscape of mRNA technologies and delivery systems for new modality therapeutics;Journal of Biomedical Science;2024-09-10

4. Optimization of polyethylene glycol shielding and mannose density on the lipid nanoparticles for efficient delivery to macrophages and spleens;International Journal of Pharmaceutics;2024-09

5. Development and applications of lipid hydrophilic headgroups for nucleic acid therapy;Biotechnology Advances;2024-09